Prostate-specific membrane antigen (PSMA)-targeted PET agents have revolutionized the care of patients with prostate cancer, supplanting traditional methods of imaging prostate cancer, and improving the selection and delivery of therapies. This has led to a rapid expansion in both the number of PSMA PET scans performed and the imaging specialists required to interpret those scans. To aid those imagers and clinicians who are new to the interpretation of PSMA PET, this review provides an overview of the interpretation of PSMA PET/CT imaging and pearls for overcoming commonly encountered pitfalls. We discuss the physiologic distribution of the clinically available PSMA-targeted radiotracers, the commonly encountered patterns of prostate cancer spread, as well as the benign and malignant mimics of prostate cancer. Additionally, we review the standardized PSMA PET reporting systems and the role of PSMA in selecting appropriate patients for PSMA-targeted therapies.
Seminars in nuclear medicine. 2023 Nov 16 [Epub ahead of print]
Andrew F Voter, Rudolf A Werner, Hatice Savas, Andrei Gafita, Ashley E Ross, Michael A Gorin, Lilja B Solnes, Martin G Pomper, Steven P Rowe, Sara Sheikhbahaei
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD., Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany., Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL., Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Department of Radiology, University of North Carolina, Chapel Hill, NC. Electronic address: .